4//SEC Filing
Lee Gary K. 4
Accession 0001209191-24-003272
CIK 0001806952other
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 8:22 PM ET
Size
11.1 KB
Accession
0001209191-24-003272
Insider Transaction Report
Form 4
Lee Gary K.
Chief Scientific Officer
Transactions
- Award
Common Stock
2024-02-09+40,000→ 52,700 total - Award
Stock Option (right to buy)
2024-02-09+400,000→ 400,000 totalExercise: $1.80Exp: 2034-02-08→ Common Stock (400,000 underlying)
Footnotes (3)
- [F1]The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Includes 4,702 shares acquired on November 18, 2022, 6,205 shares acquired on May 18, 2023 and 1,793 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F3]12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.
Issuer
Lyell Immunopharma, Inc.
CIK 0001806952
Entity typeother
Related Parties
1- filerCIK 0001907345
Filing Metadata
- Form type
- 4
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 8:22 PM ET
- Size
- 11.1 KB